New drug trial offers hope for Tough-to-Treat blood cancers
NCT ID NCT03932331
Summary
This study is testing a drug called acalabrutinib in Chinese adults whose blood cancers have returned or not responded to previous treatments. The main goals are to check the drug's safety, how the body processes it, and whether it helps control cancers like mantle cell lymphoma and chronic lymphocytic leukemia. This is an early to mid-stage study involving about 105 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE I: RELAPSED OR REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100044, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100191, China
-
Research Site
Changchun, 130021, China
-
Research Site
Changsha, 410008, China
-
Research Site
Changzhou, 272100, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Fuzhou, China
-
Research Site
Haikou, 570311, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150049, China
-
Research Site
Hefei, 230031, China
-
Research Site
Hohhot, 10050, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Suzhou, 215006, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Ürümqi, 830054, China
-
Research Site
Xining, 810007, China
-
Research Site
Zhengzhou, 450008, China
Conditions
Explore the condition pages connected to this study.